Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Reporter, APAC, Pharma insights
{62A5A61B-4135-486E-9AE4-14F5ADA58BEA}
+4 year(s) experience
Jung Won has worked previously for Dow Jones Newswires, covering various industry sectors and the economy, providing her with an ability to work to tight deadlines. She has played a key role in expanding Scrip and Pink Sheet's coverage of the important South Korean market, including biosimilar companies, emerging bioventures, and important policy, pricing and regulatory developments.
Scrip
By Jung Won Shin 16 Jan 2019
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Topic FDA Business strategies
Scrip
By Jung Won Shin 05 Dec 2018
Application of artificial intelligence to new drug development in South Korea, which has been lagging in this area, is poised to accelerate as the country moves to support and encourage the technology.
Scrip
By Jung Won Shin 22 Aug 2018
The Korean biotech’s CEO and other executives’ alleged involvement in stock price manipulation has damaged R&D credibility and shocked the domestic industry
Scrip
By Jung Won Shin 13 Jul 2018
South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen from public disclosures, and have ordered further investigation of a corporate governance decision on the handling in accounts of the JV, Samsung Bioepis. The latest ruling in the prolonged affair could hurt the credibility and business of Samsung BioLogics going forward, although the firm maintains it has done nothing improper.
Topic Policy and regulation
Scrip
By Jung Won Shin 15 May 2018
As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests.
Scrip
By Jung Won Shin 23 Aug 2017
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda.
Topic Biosimilars
Pink Sheet
By Jung Won Shin 02 Aug 2017
Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.
Topic Biosimilars Drug review
Scrip
14 Feb 2019
Scrip
12 Feb 2019
Scrip
12 Feb 2019
Scrip
31 Jan 2019
Scrip
23 Jan 2019
Scrip
23 Jan 2019
Scrip
07 Jan 2019
Pink Sheet
11 Dec 2018
Scrip
05 Dec 2018
Scrip
21 Nov 2018
Scrip
19 Nov 2018
Scrip
15 Nov 2018
Scrip
13 Nov 2018
Pink Sheet
13 Nov 2018
Scrip
06 Nov 2018
